Overview
Background
David graduated from the University of London with a BSc (Hons) in biochemistry (King’s College) and PhD which investigated the role of epidermal growth factor receptors in liver regeneration (Imperial College). Since then he has worked on a variety of projects including; immunoassay development (Ortho Clinical Diagnostics); artificial liver machine development (Imperial College); and p53 mutations in liver cancer (QIMR). He joined the Department of Nephrology at the Princess Alexandra Hospital in Brisbane in 1999. He is a senior lecturer in The University of Queensland Faculty of Medicine, a senior member of the UQ Kidney Disease Research Laboratory and manages the Princess Alexandra Hospital Endotoxin Testing Service.
His main research interests are in the area of renal tubulointerstitial fibrosis, inflammation and also the mechanisms of renal cancer development – particularly the role that cytokines and growth factors play in these processes. Current projects include the role of protease activated receptor-2 in renal scarring, inflammation and cancer, the mechanism of heavy metal toxicity in the kidney and the renoprotective properties of erythropoietin. The Princess Alexandra Hospital Endotoxin Testing Service routinely tests samples from dialysis units throughout Queensland.
Availability
- Associate Professor David Vesey is:
- Available for supervision
Fields of research
Qualifications
- Bachelor of Biochemistry, King's College London
- Doctor of Philosophy of Gastroenterology and Hepatology, Imperial College London
Works
Search Professor David Vesey’s works on UQ eSpace
2010
Conference Publication
Essential metals and cadmium toxicity in the kidney
Vesey, David (2010). Essential metals and cadmium toxicity in the kidney. Thailand Reverse Brain Drain Project International Conference on Cadmium in Food and Human Health, Phitsanulok, Thailand, 15-17 January 2010. Phitsanulok, Thailand: Naresuan University.
2010
Conference Publication
Protease-activated receptor-2 and renal carcinogenesis
Vesey, D., Rajandram, R., Blakeney, J., Suen, J., Johnson, D., Fairlie, D. and Gobe, G. (2010). Protease-activated receptor-2 and renal carcinogenesis. 46th Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology, Perth Convention and Exhibition Centre, Perth, Western Australia, 12-15 September 2010. Richmond, Vic., Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/j.1440-1797.2010.01377_1.x
2010
Conference Publication
A Novel Protease-Activated Receptor-2 Antagonist Targeting Inflammation and Proliferation in Human Renal Tubular Epithelial Cells
Vesey David A., Suen, Jacky Yung, Johnson, David W. and Fairlie, David (2010). A Novel Protease-Activated Receptor-2 Antagonist Targeting Inflammation and Proliferation in Human Renal Tubular Epithelial Cells. Kidney Week, American society of Nephrology, Denver Colorado USA, November 16 - 21. Journal of the American Society of Nephrology:
2009
Book Chapter
Isolation and primary culture of human proximal tubule cells
Vesey, David A., Qi, Weier, Chen, Xingming, Pollock, Carol A. and Johnson, David W. (2009). Isolation and primary culture of human proximal tubule cells. Kidney Research: Experimental Protocols. (pp. 19-24) edited by John M. Walker, T. D. Hewitson and G. J. Becker. Clifton, NJ, U.S.A.: Humana Press. doi: 10.1007/978-1-59745-352-3_2
2009
Conference Publication
Functional significance of TRAF1 knockdown in renal cell carcinoma anti-cancer treatment
Gobe, Glenda C., Rajandram, Retnagowri, Vesey, David A., Wang, Zhiqiang, Bennett, Nigel and Johnson, David W. (2009). Functional significance of TRAF1 knockdown in renal cell carcinoma anti-cancer treatment. American Society of Nephrology Renal Week: 42nd Annual Meeting & Scientific Exposition, San Diego, CA, U.S.A., 27 October - 1 November, 2009. Washington , D.C., U.S.A.: American Society of Nephrology.
2008
Conference Publication
Recombinant human erythropoietin increases vascular expression of nestin and decreases oxidant-induced endothelial injury in models of ischemic acute kidney injury
Gobe, G. C., Yamada, M., Vesey, D. A. and Johnson, D. W. (2008). Recombinant human erythropoietin increases vascular expression of nestin and decreases oxidant-induced endothelial injury in models of ischemic acute kidney injury. 11th Asian-Pacific Congress of Nephrology, Kuala Lumpur, Malaysia, 5–8 May 2008. Carlton, Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/j.1440-1797.2008.00954.x
2008
Conference Publication
Recombinant human erythropoietin reduces ischemic acute kidney injury but does not ameliorate progression to chronic kidney disease
Gobe, GC, Vesey, DA, Bennett, NC and Johnson, DW (2008). Recombinant human erythropoietin reduces ischemic acute kidney injury but does not ameliorate progression to chronic kidney disease. 11th Asian Pacific Congress of Nephrology, incorporating the 15th Asian Colloquium in Nephrology and 2nd Asian Forum of CKD Initiative, Kuala Lumpur, Malaysia, 5–8 May 2008. Richmond, VIC, Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/j.1440-1797.2008.00953.x
2008
Conference Publication
Recombinant human erythropoietin reduces ischemic acute kidney injury but does not stop progression to chronic kidney disease
Bennett, N., Colditz, P., Gobe, G. C., Johnson, D., Patel, J. and Vesey, D. A. (2008). Recombinant human erythropoietin reduces ischemic acute kidney injury but does not stop progression to chronic kidney disease. 44th Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology, Newcastle, Australia, 6-10 September 2008. HOBOKEN: Australian and New Zealand Society of Nephrology (ANZSN). doi: 10.1111/j.1440-1797.2008.001013.x
2008
Conference Publication
Modulation of vascular nestin and oxidant-induced endothelial injury by human recombinant erythropoietin in models of ischemic acute kidney injuryo-inflammatory and proliferative responses
Gobe, Glenda C., Bennett, Nigel, Patel, Jatin, Colditz, Paul, Vesey, David A. and Johnson, David W. (2008). Modulation of vascular nestin and oxidant-induced endothelial injury by human recombinant erythropoietin in models of ischemic acute kidney injuryo-inflammatory and proliferative responses. Renal Week 2008: American Society of Nephrology Annual Meeting, Philadephia, USA, 14 - 19 November, 2008. Washington, D. C., USA: American Society of Nephrology.
2008
Conference Publication
Recombinant human erythropoietin reduces ischemic acute kidney injury but does not ameliorate progression to chronic kidney disease
Gobe, G. C., Vesey, D. A., Bennett, N. C. and Johnson, D. W. (2008). Recombinant human erythropoietin reduces ischemic acute kidney injury but does not ameliorate progression to chronic kidney disease. 11th Asian Pacific Congress of Nephrology (APCN), Kuala Lumpur, Malaysia, 4-7 May 2008. Carlton, VIC, Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/j.1440-1797.2008.00953.x
2007
Journal Article
Erythropoietin reduces cisplatin-induced apoptosis in renal carcinoma cells via a PKC dependent pathway
Li, Jun, Vesey, David A., Johnson, David W. and Gobe, Glenda C. (2007). Erythropoietin reduces cisplatin-induced apoptosis in renal carcinoma cells via a PKC dependent pathway. Cancer Biology Therapy, 6 (12), 1944-1950. doi: 10.4161/cbt.6.12.4975
2007
Journal Article
Proinflammatory and proliferative responses of human proximal tubule cells to PAR-2 activation
Vesey, David A., Kruger, Wade A., Poronnik, Philip, Gobe, Glenda C. and Johnson, David W. (2007). Proinflammatory and proliferative responses of human proximal tubule cells to PAR-2 activation. American Journal of Physiology: Renal Physiology, 293 (5), F1441-F1449. doi: 10.1152/ajprenal.00088.2007
2007
Journal Article
Therapeutic value of orally administered silibinin in renal cell carcinoma: Manipulation of insulin-like growth factor binding protein-3 levels
Cheung, Catherine W., Taylor, Paul J., Kirkpatrick, Carl M.J., Vesey, David A., Gobe, Glenda C., Winterford, Clay, Nicol, David L. and Johnson, David W. (2007). Therapeutic value of orally administered silibinin in renal cell carcinoma: Manipulation of insulin-like growth factor binding protein-3 levels. BJU International, 100 (2), 438-444. doi: 10.1111/j.1464-410X.2007.07012.x
2007
Journal Article
Apoptosis of tubulointerstitial chronic inflammatory cells in progressive renal fibrosis after cancer therapies
Yang, Tao, Vesey, David A., Johnson, David W., Wei, Ming Q. and Gobe, Glenda C. (2007). Apoptosis of tubulointerstitial chronic inflammatory cells in progressive renal fibrosis after cancer therapies. Translational Research, 150 (1), 40-50. doi: 10.1016/j.trsl.2007.01.006
2007
Journal Article
Isolation, propagation and characterization of primary tubule cell culture from human kidney (Methods in Renal Research)
Qi, Weier, Johnson, David W., Vesey, David A., Pollock, Carol A. and Chen, Xinming (2007). Isolation, propagation and characterization of primary tubule cell culture from human kidney (Methods in Renal Research). Nephrology, 12 (2), 155-159. doi: 10.1111/j.1440-1797.2007.00779.x
2007
Journal Article
Potential physiological and pathophysiological roles for protease-activated receptor-2 in the kidney
Vesey, David A., Hooper, John D., Gobe, Glenda C. and Johnson, David W. (2007). Potential physiological and pathophysiological roles for protease-activated receptor-2 in the kidney. Nephrology, 12 (1), 36-43. doi: 10.1111/j.1440-1797.2006.00746.x
2007
Journal Article
Silibinin inhibits renal cell carcinoma via mechanisms that are independent if insulin-like growth factor-binding protein 3
Cheung, Catherine W., Vesey, David A., Nicol, David L. and Johnson, David W. (2007). Silibinin inhibits renal cell carcinoma via mechanisms that are independent if insulin-like growth factor-binding protein 3. BJU International, 99 (2), 454-460. doi: 10.1111/j.1464-410X.2007.06571.x
2007
Conference Publication
The effect of recombinant human erythropoietin (rhEPO) in renal cell carcinoma (RCC) chemotherapy
Li, J., Vesey, D. A., Johnson, D. W. and Gobe, G. C. (2007). The effect of recombinant human erythropoietin (rhEPO) in renal cell carcinoma (RCC) chemotherapy. World Congress of Nephrology, Rio De Janeiro, Brazil, 21-25 April , 2007. International Society of Nephrology (ISN).
2007
Conference Publication
Erythropoietin: Novel applications beyond anaemia treatment
Vesey, D. A., Gobe, G. C. and Johnson, D. W. (2007). Erythropoietin: Novel applications beyond anaemia treatment. 2nd International Conference of Naresuan University, Phitsanulok, Thailand, 27-28 July, 2007.
2007
Conference Publication
The effect of recombinant human erythropoietin (rhEPO) in renal cell carcinoma (RCC) chemotherapy
Li, J., Vesey, D. A., Johnson, D. W. and Gobe, G. C. (2007). The effect of recombinant human erythropoietin (rhEPO) in renal cell carcinoma (RCC) chemotherapy. 32nd Lorne Conference on Protein Structure and Function, Lorne, Victoria, Australia, 4-8 February 2007. Lorne, Vic., Australia:
Funding
Past funding
Supervision
Availability
- Associate Professor David Vesey is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Supervision history
Current supervision
-
Doctor Philosophy
Exploring magnetic resonance for differentiating between progressive and non-progressive chronic kidney disease
Associate Advisor
Other advisors: Professor Graham Galloway, Associate Professor Ross Francis, Dr Robert Ellis
Completed supervision
-
2021
Doctor Philosophy
Clinical Biobanking and the Distinguishing Risk of Progressive Chronic Kidney Disease Study
Associate Advisor
-
2020
Doctor Philosophy
The role of the adipose tissue microenvironment in kidney cancer
Associate Advisor
Other advisors: Professor David Johnson, Dr Sumaira Hasnain
-
2020
Doctor Philosophy
Exploring Resistance of Renal Cell Carcinoma to Sunitinib Therapy
Associate Advisor
-
2016
Doctor Philosophy
Bioactive compounds from Australian Blacklip Abalone (Haliotis rubra) processing waste
Associate Advisor
-
2009
Doctor Philosophy
Targeting genes for identification and treatment of renal cell carcinoma
Associate Advisor
Other advisors: Professor David Johnson
Media
Enquiries
For media enquiries about Associate Professor David Vesey's areas of expertise, story ideas and help finding experts, contact our Media team: